[go: up one dir, main page]

LUC00112I2 - - Google Patents

Download PDF

Info

Publication number
LUC00112I2
LUC00112I2 LU00112C LUC00112C LUC00112I2 LU C00112 I2 LUC00112 I2 LU C00112I2 LU 00112 C LU00112 C LU 00112C LU C00112 C LUC00112 C LU C00112C LU C00112 I2 LUC00112 I2 LU C00112I2
Authority
LU
Luxembourg
Application number
LU00112C
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of LUC00112I1 publication Critical patent/LUC00112I1/fr
Publication of LUC00112I2 publication Critical patent/LUC00112I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57527—Calcitonin gene related peptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57545—Neuropeptide Y
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
LU00112C 2010-06-10 2019-04-09 LUC00112I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35332310P 2010-06-10 2010-06-10
PCT/US2011/039381 WO2011156324A1 (fr) 2010-06-10 2011-06-07 Anticorps anti-cgrp

Publications (2)

Publication Number Publication Date
LUC00112I1 LUC00112I1 (fr) 2019-04-10
LUC00112I2 true LUC00112I2 (fr) 2019-12-27

Family

ID=45096388

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00112C LUC00112I2 (fr) 2010-06-10 2019-04-09

Country Status (33)

Country Link
US (3) US9073991B2 (fr)
EP (2) EP3318272B1 (fr)
JP (2) JP6021806B2 (fr)
KR (1) KR101489566B1 (fr)
CN (2) CN104292332B (fr)
AR (1) AR081434A1 (fr)
AU (1) AU2011265050B2 (fr)
BR (1) BR112012031501B1 (fr)
CA (1) CA2802102C (fr)
CY (2) CY1119789T1 (fr)
DK (1) DK2579894T3 (fr)
EA (1) EA022931B1 (fr)
ES (2) ES2930321T3 (fr)
HR (1) HRP20171992T1 (fr)
HU (2) HUE038135T2 (fr)
IL (2) IL222885B (fr)
JO (1) JO3330B1 (fr)
LT (2) LT2579894T (fr)
LU (1) LUC00112I2 (fr)
ME (1) ME02862B (fr)
MX (2) MX340999B (fr)
NL (1) NL300979I2 (fr)
NO (2) NO2579894T3 (fr)
NZ (1) NZ603607A (fr)
PL (1) PL2579894T3 (fr)
PT (1) PT2579894T (fr)
RS (1) RS56638B1 (fr)
SG (1) SG185648A1 (fr)
SI (1) SI2579894T1 (fr)
TW (1) TWI423818B (fr)
UA (1) UA109658C2 (fr)
WO (1) WO2011156324A1 (fr)
ZA (1) ZA201208996B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1957106B2 (fr) 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
JP5537441B2 (ja) 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
KR101519192B1 (ko) 2009-08-28 2015-05-11 리나트 뉴로사이언스 코프. 칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp
DK2709663T3 (da) 2011-05-20 2019-05-20 Alderbio Holdings Llc Anvendelse af anti-CGRP-antistoffer og antistoffragmenter til forebyggelse eller inhibering af fotofobi eller aversion mod lys hos individer med behov herfor, især migrænikere
SG10201604040PA (en) 2011-05-20 2016-07-28 Alderbio Holdings Llc Anti-cgrp compositions and use thereof
US9855332B2 (en) 2011-05-20 2018-01-02 Alderbio Holdings Llc Use of anti-CGRP antibodies and antibody fragments to treat diarrhea in subjects with diseases or treatments that result in elevated CGRP levels
KR102134088B1 (ko) 2012-08-24 2020-07-14 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
US20170114122A1 (en) 2015-10-23 2017-04-27 Alderbio Holdings Llc Regulation of glucose metabolism using anti-cgrp antibodies
SI3119431T1 (sl) 2014-03-21 2024-06-28 Teva Pharmaceuticals International Gmbh Antagonistična protitelesa, usmerjena proti peptidu, povezanemu z genom za kalcitonin, in postopki za uporabo le-teh
US10556945B2 (en) * 2014-03-21 2020-02-11 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
MX382408B (es) 2014-10-24 2025-03-13 Merck Sharp & Dohme Llc Coagonistas de los receptores de glucagón y de glp-1.
TWI595006B (zh) * 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
JOP20200116A1 (ar) 2015-04-24 2017-06-16 Amgen Inc طرق لعلاج أو الوقاية من الصداع النصفي
AR104847A1 (es) * 2015-06-17 2017-08-16 Lilly Co Eli Formulación de anticuerpo anti-cgrp
WO2017074428A1 (fr) * 2015-10-30 2017-05-04 Eli Lilly And Company Anticorps bispécifiques anti-cgrp/anti-il-23 et leurs utilisations
CN105483091A (zh) * 2015-12-29 2016-04-13 天津三箭生物技术股份有限公司 小鼠抗人Calcitonin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株
KR20180091930A (ko) * 2016-01-28 2018-08-16 일라이 릴리 앤드 캄파니 Cgrp 항체 및 그의 용도
CN108601833B (zh) 2016-02-01 2022-11-15 伊莱利利公司 甲状旁腺激素-抗rankl抗体融合化合物
US10688181B2 (en) 2016-06-27 2020-06-23 The Regents Of The University Of California Cancer treatment combinations
PE20191148A1 (es) 2016-09-23 2019-09-02 Teva Pharmaceuticals Int Gmbh Tratamiento de la migrana refractaria
MX2019003338A (es) 2016-09-23 2019-09-26 Teva Pharmaceuticals Int Gmbh Tratamiento de cefalea en racimos.
US10766952B2 (en) 2017-03-02 2020-09-08 Beth Israel Deaconess Medical Center, Inc. Methods for reducing migraine frequency in a subject in need thereof
TW201902926A (zh) * 2017-05-03 2019-01-16 美商美國禮來大藥廠 抗cgrp／抗il-23雙特異性抗體及其用途
US11426706B2 (en) 2017-06-21 2022-08-30 Cephalon, Inc. Cation exchange chromatography wash buffer
TWI754772B (zh) * 2017-09-06 2022-02-11 美商美國禮來大藥廠 用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
JP7339262B2 (ja) 2018-01-12 2023-09-05 アムジェン インコーポレイテッド Ｐａｃ１抗体及びその使用
WO2019231800A1 (fr) 2018-05-31 2019-12-05 Eli Lilly And Company Anticorps anti-cgrp pour le traitement des migraines liées aux menstruations
US20210340230A1 (en) 2018-08-22 2021-11-04 Eli Lilly And Company Anti-CGRP Antibodies For Treatment-Resistant Patients
CR20210373A (es) 2019-01-08 2021-08-19 H Lundbeck As Tratamiento agudo y tratamiento rápido de la cefalea usando anticuerpos anti-cgrp
EP3744400A1 (fr) * 2019-05-28 2020-12-02 Etablissement Français du Sang Ciblage de cellules car-t il-1rap et leur utilisation dans la leucémie myéloïde aiguë (aml)
CN114127110B (zh) * 2019-05-30 2022-07-01 山东博安生物技术股份有限公司 抗cgrp抗体及其应用
CA3154522A1 (fr) 2019-10-15 2021-04-22 Christopher Carl Frye Lignees cellulaires mammiferes deficientes en lipase/esterase modifiees par recombinaison
AU2020202454A1 (en) 2020-04-06 2021-10-21 H. Lundbeck A/S Treatment of most bothersome symptom (MBS) associated with migraine using anti-CGRP antibodies
EP4301362A1 (fr) 2021-03-02 2024-01-10 CGRP Diagnostics GmbH Traitement et/ou réduction de l'apparition de migraine
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.
EP4570913A1 (fr) * 2022-08-11 2025-06-18 Shanghai Junshi Biosciences Co., Ltd. Anticorps anti-cgrp et utilisation
CN118271438B (zh) * 2024-05-27 2024-08-30 上海宏成药业有限公司 抗cgrp抗体或其抗原结合片段及其用途
CN119320450B (zh) * 2024-12-13 2025-07-25 中国人民解放军军事科学院军事医学研究院 针对降钙素基因相关肽的抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP3370324B2 (ja) * 1991-04-25 2003-01-27 中外製薬株式会社 ヒトインターロイキン−６受容体に対する再構成ヒト抗体
JP4124480B2 (ja) * 1991-06-14 2008-07-23 ジェネンテック・インコーポレーテッド 免疫グロブリン変異体
WO2005035753A1 (fr) 2003-10-10 2005-04-21 Chugai Seiyaku Kabushiki Kaisha Anticorps a double specificite remplaçant une proteine fonctionnelle
CA2603940A1 (fr) * 2005-04-08 2006-10-19 Nancy Ulbrandt Anticorps diriges contre le metapneumovirus du mammifere
EP1957106B2 (fr) * 2005-11-14 2019-07-24 Teva Pharmaceuticals International GmbH Anticorps antagonistes orientes contre un peptide lie au gene de la calcitonine, et procedes d'utilisation correspondants
WO2007076336A1 (fr) * 2005-12-22 2007-07-05 Eli Lilly And Company Traitement de la migraine avec des anticorps anti-cgrp
JP5537441B2 (ja) * 2008-03-04 2014-07-02 ファイザー・リミテッド 慢性疼痛を治療する方法
CA2716799C (fr) * 2008-03-04 2018-05-22 Pfizer Limited Procedes de traitement d'une douleur inflammatoire
JO3330B1 (ar) * 2010-06-10 2019-03-13 Lilly Co Eli الأجسام المضادة cgrp

Also Published As

Publication number Publication date
CN104292332B (zh) 2019-11-01
ES2930321T3 (es) 2022-12-09
NL300979I1 (nl) 2019-04-17
JP2013532143A (ja) 2013-08-15
MX2012014480A (es) 2013-02-07
WO2011156324A1 (fr) 2011-12-15
AU2011265050B2 (en) 2013-06-27
IL242409B (en) 2020-07-30
JP2017014203A (ja) 2017-01-19
LTC2579894I2 (lt) 2020-03-25
RS56638B1 (sr) 2018-03-30
HK1203211A1 (en) 2015-10-23
JP6021806B2 (ja) 2016-11-09
CY2019017I2 (el) 2020-05-29
NL300979I2 (nl) 2019-07-11
NO2019017I1 (no) 2019-04-05
EP2579894B1 (fr) 2017-11-22
BR112012031501B1 (pt) 2020-02-11
US20110305711A1 (en) 2011-12-15
TWI423818B (zh) 2014-01-21
AU2011265050A1 (en) 2012-11-08
EA022931B1 (ru) 2016-03-31
ZA201208996B (en) 2014-05-28
ES2656000T3 (es) 2018-02-22
EA201270769A1 (ru) 2013-04-30
CA2802102C (fr) 2016-07-26
KR101489566B1 (ko) 2015-02-03
LTPA2019011I1 (lt) 2019-05-10
TW201210618A (en) 2012-03-16
CY1119789T1 (el) 2018-06-27
EP3318272A1 (fr) 2018-05-09
NZ603607A (en) 2014-09-26
EP2579894A4 (fr) 2013-12-04
AR081434A1 (es) 2012-08-29
CN104292332A (zh) 2015-01-21
NO2579894T3 (fr) 2018-04-21
HUE038135T2 (hu) 2018-09-28
CN102946905B (zh) 2014-10-15
UA109658C2 (xx) 2015-09-25
US9505838B2 (en) 2016-11-29
MX340999B (es) 2016-08-03
JO3330B1 (ar) 2019-03-13
IL222885B (en) 2019-09-26
KR20130034024A (ko) 2013-04-04
LT2579894T (lt) 2018-02-26
HRP20171992T1 (hr) 2018-02-09
CN102946905A (zh) 2013-02-27
EP2579894A1 (fr) 2013-04-17
DK2579894T3 (en) 2018-01-15
CY2019017I1 (el) 2020-05-29
EP3318272B1 (fr) 2022-08-10
CA2802102A1 (fr) 2011-12-15
US20150259415A1 (en) 2015-09-17
SI2579894T1 (en) 2018-01-31
HUS1900020I1 (hu) 2019-05-28
JP6466883B2 (ja) 2019-02-06
ME02862B (fr) 2018-04-20
US9073991B2 (en) 2015-07-07
PT2579894T (pt) 2018-02-06
US20170073403A1 (en) 2017-03-16
BR112012031501A2 (pt) 2016-10-25
PL2579894T3 (pl) 2018-04-30
MX363209B (es) 2019-03-14
IL222885A0 (en) 2012-12-31
SG185648A1 (en) 2012-12-28
LUC00112I1 (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
LUC00112I2 (fr)
BR112013008959A2 (fr)
BR112012030039A2 (fr)
BR112012028408A2 (fr)
BR112012029986A2 (fr)
BR112012027808A2 (fr)
BR112012024897A2 (fr)
BR112012026492A2 (fr)
BR112012031500A2 (fr)
BR112012025307A2 (fr)
BR112012026946A2 (fr)
BR112012025482A2 (fr)
BR112013006400A2 (fr)
BR112012031826A2 (fr)
BR112012023249A2 (fr)
BR112012028186A2 (fr)
BR112012025577A2 (fr)
BR112012027015A2 (fr)
BR112012025308A2 (fr)
BR112012027945A2 (fr)
BR112013010949A2 (fr)
BR112012024872A2 (fr)
BR112012023265A2 (fr)
BR112012026403A2 (fr)
BR112013003284A2 (fr)